463 related articles for article (PubMed ID: 19695395)
1. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder.
Bereza BG; Machado M; Einarson TR
Clin Ther; 2009 Jun; 31(6):1279-308. PubMed ID: 19695395
[TBL] [Abstract][Full Text] [Related]
2. Modelling the population cost-effectiveness of current and evidence-based optimal treatment for anxiety disorders.
Issakidis C; Sanderson K; Corry J; Andrews G; Lapsley H
Psychol Med; 2004 Jan; 34(1):19-35. PubMed ID: 14971624
[TBL] [Abstract][Full Text] [Related]
3. Human and economic burden of generalized anxiety disorder.
Hoffman DL; Dukes EM; Wittchen HU
Depress Anxiety; 2008; 25(1):72-90. PubMed ID: 17146763
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Iskedjian M; Walker JH; Bereza BG; Le Melledo JM; Einarson TR
Curr Med Res Opin; 2008 May; 24(5):1539-48. PubMed ID: 18416886
[TBL] [Abstract][Full Text] [Related]
5. Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options.
Flint AJ
Drugs Aging; 2005; 22(2):101-14. PubMed ID: 15733018
[TBL] [Abstract][Full Text] [Related]
6. Is complementary and alternative medicine (CAM) cost-effective? A systematic review.
Herman PM; Craig BM; Caspi O
BMC Complement Altern Med; 2005 Jun; 5():11. PubMed ID: 15932647
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
Fernandez JL; Montgomery S; Francois C
Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
[TBL] [Abstract][Full Text] [Related]
8. Generalized anxiety disorder: prevalence, burden, and cost to society.
Wittchen HU
Depress Anxiety; 2002; 16(4):162-71. PubMed ID: 12497648
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of generalized anxiety disorders].
Etchegaray M; Hardy P
Presse Med; 2008 May; 37(5 Pt 2):859-66. PubMed ID: 18378113
[TBL] [Abstract][Full Text] [Related]
10. [Anxiety disorders in private practice psychiatric out-patients: prevalence, comorbidity and burden (DELTA study)].
Pélissolo A; André C; Chignon JM; Dutoit D; Martin P; Richard-Berthe C; Tignol J
Encephale; 2002; 28(6 Pt 1):510-9. PubMed ID: 12506263
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom.
Guest JF; Russ J; Lenox-Smith A
Eur J Health Econ; 2005 Jun; 6(2):136-45. PubMed ID: 15682285
[TBL] [Abstract][Full Text] [Related]
12. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care.
Joesch JM; Sherbourne CD; Sullivan G; Stein MB; Craske MG; Roy-Byrne P
Psychol Med; 2012 Sep; 42(9):1937-48. PubMed ID: 22152230
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of generalized anxiety: new pharmacologic approaches].
Boulenger JP
Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
[TBL] [Abstract][Full Text] [Related]
14. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care.
Craske MG; Stein MB; Sullivan G; Sherbourne C; Bystritsky A; Rose RD; Lang AJ; Welch S; Campbell-Sills L; Golinelli D; Roy-Byrne P
Arch Gen Psychiatry; 2011 Apr; 68(4):378-88. PubMed ID: 21464362
[TBL] [Abstract][Full Text] [Related]
15. A systematic literature review on the health-related quality of life and economic burden of Fabry disease.
Jovanovic A; Miller-Hodges E; Castriota F; Takyar S; Howitt H; Ayodele O
Orphanet J Rare Dis; 2024 Apr; 19(1):181. PubMed ID: 38689282
[TBL] [Abstract][Full Text] [Related]
16. Cost of anxiety disorders: impact of comorbidity.
Souêtre E; Lozet H; Cimarosti I; Martin P; Chignon JM; Adès J; Tignol J; Darcourt G
J Psychosom Res; 1994; 38 Suppl 1():151-60. PubMed ID: 7799247
[TBL] [Abstract][Full Text] [Related]
17. Generalized anxiety disorder. An important clinical concern.
Hidalgo RB; Davidson JR
Med Clin North Am; 2001 May; 85(3):691-710. PubMed ID: 11349480
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom.
Jørgensen TR; Stein DJ; Despiegel N; Drost PB; Hemels ME; Baldwin DS
Ann Pharmacother; 2006 Oct; 40(10):1752-8. PubMed ID: 16985090
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.
Ruger JP; Emmons KM
Value Health; 2008; 11(2):180-90. PubMed ID: 17854435
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluations and randomized trials in spinal disorders: principles and methods.
Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
